EGFR as a Prognostic Factor in Ovarian Cancer
Author Information
Author(s): Aurelia Noske, Michael Schwabe, Wilko Weichert, Silvia Darb-Esfahani, Ann-Christin Buckendahl, Jalid Sehouli, Elena I Braicu, Jan Budczies, Manfred Dietel, Carsten Denkert
Primary Institution: Institute of Pathology, University Hospital Charité Berlin, Germany
Hypothesis
Does EGFR expression have prognostic value in ovarian carcinomas?
Conclusion
Membranous EGFR expression is an independent prognostic factor for poor overall survival in ovarian cancer patients.
Supporting Evidence
- Membranous EGFR was found in 36.4% of ovarian carcinomas.
- Membranous EGFR expression was significantly associated with shorter overall survival.
- In serous ovarian carcinomas, membranous EGFR expression was related to poor overall survival with a hazard ratio of 4.6.
Takeaway
This study found that a specific protein called EGFR can help predict how well patients with ovarian cancer will do. If they have a lot of this protein, they might not live as long.
Methodology
The study analyzed EGFR expression in 121 ovarian carcinoma samples using immunohistochemistry and evaluated its association with patient survival.
Limitations
The study did not find associations between EGFR expression and standard clinico-pathological factors.
Participant Demographics
Mean age of participants was 57 years, with a range from 33 to 80; 66.1% had serous carcinoma.
Statistical Information
P-Value
0.002
Confidence Interval
HR 2.7, CI 1.1-6.4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website